Impact of Telemedicine During the COVID-19 Pandemic on Patient Attendance.

In response to Dr. Robert F. Kushners early observations in What COVID-19 is Teaching Us About Counseling for Weight Management (1), we providers at the Comprehensive Weight Control Center at Weill Cornell Medicine in New York, New York, and the Center for Weight Management at Scripps Health in San Diego, California, sought to explore the shifts in patient volume and attendance since telemedicine conversion (2). [...]obesity being a risk factor for increased COVID-19 severity could be incentivizing patients to prioritize obesity treatment (4). Disclosure: LA declared receiving consulting fees from, and serving on, advisory boards for ERX, Jamieson Laboratories, Pfizer, Novo Nordisk, Sanofi, Janssen, UnitedHealth Group Ventures, and Gelesis;receiving research funding from Lilly, Janssen, Allurion, and Novo Nordisk;having an equity interest in Intellihealth, ERX, Zafgen, Gelesis, MYOS, and Jamieson Laboratories;and serving on a board of directors for MYOS, Intellihealth, and Jamieson Laboratories outside the doi: 10.1002/oby.23180 1 Division of Endocrinology, Weill Cornell Medicine, Comprehensive Weight Control Center, New York, New York, USA.